Market Intelligence, Clinical Progress, and High-Purity Reagents for Spinocerebellar Ataxia Type 1 (SCA1) Development.
Target Overview: ATXN1 Functional Domains and Key Mutations
ATXN1 (Ataxin-1) is the protein product of the ATXN1 gene, whose polyglutamine (polyQ) expansion causes Spinocerebellar Ataxia Type 1 (SCA1). The protein contains an AXH domain (UniProt P54253) involved in RNA binding and protein-protein interactions. Key mutations include dbSNP:rs11969612 and dbSNP:rs16885, which may impact protein stability or function. These features underpin the design of disease-relevant reagents and assays.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ATXN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATXN1 Mutant Recombinant Proteins: Pathogenic PolyQ expansion (Q82), WT (Q30), S776A/E phospho-variants. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View ATXN1 Products |
| Gene Delivery | ATXN1 Promise-ORF / Lentivirus: Full-length ORF with pathogenic expansion or WT for stable cell lines. | View ATXN1 Products |
| Benchmark Ab | Anti-ATXN1 (Research Monoclonal): Recombinant positive control for polyQ-expanded and total ATXN1 detection. | View ATXN1 Products |
| Validator | ATXN1 siRNA Set: For knockdown verification and ASO benchmarking. | View ATXN1 Products |
| Related Target A | ATXN2: Synergistic polyQ pathway; co-regulated RNA foci and stress granule biology. | View ATXN2 Products |
| Related Target B | ATXN3: Shared polyQ neurodegeneration mechanism; SCA3 pathway comparator. | View ATXN3 Products |
| Related Target C | CIC: Core ATXN1 interactor; transcriptional repressor complex validation. | View CIC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PolyQ length-dependent aggregation & pathology | Purified WT (Q30) and pathogenic expansion (Q82) proteins, >95% purity, sequence verified by mass spec |
| S776 phosphorylation mechanistic studies | Phospho-dead (S776A) and phospho-mimetic (S776E) mutants available for mechanism-of-action assays |
| Lack of intracellular disease models | Lentiviral ORF particles for stable ATXN1-overexpressing neuronal/HEK cell line construction |
| Lack of Controls | Clinical-grade Benchmark Antibodies (research monoclonals) and siRNA validators included |
| False Positives in aggregation assays | Validated siRNA included for specificity checks; WT vs mutant protein controls |
| Intracellular degradation validation (PROTAC) | Lentivirus Premade Particles optimized for stable cell line construction in PROTAC / Molecular Glue screening |
Live ATXN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ATXN1 therapeutics is intensifying, with major players shifting focus from symptomatic management to genetic silencing and intracellular degradation. As first-generation antisense oligonucleotide (ASO) and AAV-delivered RNAi programs advance through preclinical and early clinical stages, the next wave of R&D is targeting allele-selective knockdown, blood-brain barrier (BBB) penetration, and targeted protein degradation (PROTAC/LYTAC) strategies to clear aggregated ATXN1. Because ATXN1 is an intracellular, nuclear-localizing protein, standard monoclonal antibodies are ineffective, driving innovation in nucleic acid and degradation modalities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO / RNAi | Ionis, Biogen, Vico Therapeutics | Spinocerebellar Ataxia Type 1 | Allele-selective knockdown validation (Need WT vs Q82 Mutant Proteins & Lentivirus cell models) |
| AAV Gene Therapy | Lacerta Therapeutics, Spark Therapeutics | SCA1 (CNS) | In vivo expression validation (Need full-length ORF Lentivirus for stable line screening) |
| Small Molecule (Splicing/ Stability) | Novartis, PTC Therapeutics | SCA1, PolyQ Diseases | S776 phosphorylation-state assay (Need S776A/E Mutant Proteins for selectivity profiling) |
| PROTAC / Degrader | Arvinas, Pre-clinical Academia | SCA1 | Intracellular aggregation clearance assay (Need high-purity mutant antigens for ternary complex SPR) |
Molecular Differentiation & Assay Strategy (Targeted Insights)
To achieve best-in-class therapy, ATXN1 drug candidates must demonstrate differentiation in the following dimensions:
- Affinity & PolyQ Selectivity – Agents must distinguish between WT (Q30) and pathogenic (Q39+, e.g. Q82) proteins. Use TarMart's Q30 and Q82 recombinant proteins in SPR/BLI head-to-head binding assays.
- PTM Mechanism (S776) – S776 phosphorylation promotes nuclear localization and aggregation. Use S776A (phospho-dead) and S776E (phospho-mimetic) mutants for mechanism-of-action and inhibitor screening.
- Intracellular Aggregation Clearance – Cell-based models (lentivirus-derived stable lines) are essential for evaluating penetration and aggregate clearance of PROTACs or CPP-conjugated molecules.
- Off-target Safety – ATXN1 shares structural homology with ATXN2, ATXN3. Use high-purity recombinant ATXN2/ATXN3 proteins for cross-reactivity panels to ensure specificity.
Conclusion
TarMart provides a comprehensive, high-quality reagent ecosystem for ATXN1 drug discovery, covering pathogenic PolyQ and phosphorylation mutants, lentiviral cell models, benchmark antibodies, siRNA validators, and closely related target proteins (ATXN2, ATXN3, CIC). This integrated toolkit addresses the critical assay needs of ASO/RNAi, AAV gene therapy, small molecule, and PROTAC modalities, accelerating the path to disease-modifying therapies for SCA1.